Skip to content

Positive Phase 2b Trial of Pharmalink’s Nefecon in IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

Non Regulatory

Pharmalink AB, a specialty pharma company, is pleased to announce that its recent publication in The Lancet on the positive Phase 2b trial of Nefecon® in primary IgA nephropathy (IgAN) patients, has been selected for presentation at the upcoming European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) conference (Madrid, Spain; June 3-6, 2017).

The Phase 2b trial (known as the NEFIGAN trial), will be presented in a special session co-hosted by The Lancet by lead author Bengt Fellström, MD, PhD, Professor of Nephrology at Uppsala University Hospital and Principal Investigator of the NEFIGAN Trial.

Title: Effects of a novel targeted release formulation of budesonide vs. placebo in IgA nephropathy: The NEFIGAN randomised clinical trial.
Session: The Lancet/ERA-EDTA Symposium
Date: Sunday, June 4, 2017
Time: 15:15-16:45 CET
Location: Hall 10.A
Prof. Fellström will give a second presentation of results from the NEFIGAN trial at the conference.

Title: Proteinuria reduction in IgA nephropathy by Nefecon, a targeted release formulation of budesonide – results from the NEFIGAN trial
Session: Glomerulonephritis
Date: Tuesday, June 6, 2017
Time: 8.00-9.30 CET
Location: Sala Neptuno